Skip to main content
Top
Published in: BMC Psychiatry 1/2011

Open Access 01-12-2011 | Research article

Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study

Authors: Gebra B Cuyún Carter, Denái R Milton, Haya Ascher-Svanum, Douglas E Faries

Published in: BMC Psychiatry | Issue 1/2011

Login to get access

Abstract

Background

This study of chronically ill patients with schizophrenia aimed to identify patients who achieve sustained favorable long-term outcome - when the outcome incorporates severity of symptoms, level of functioning, and use of acute care services - and to identify the best baseline predictors of achieving this sustained favorable long-term outcome.

Methods

Using data from the United States Schizophrenia Care and Assessment Program (US-SCAP) (N = 2327), a large 3-year prospective, multisite, observational study of individuals treated for schizophrenia in the US, a hierarchical cluster analysis was performed to group patients based upon baseline symptom severity. Symptom severity was assessed using the Positive and Negative Syndrome Scale (PANSS) scores, level of functioning, and use of acute care services. Level of functioning reflected patient-reported productivity and clinician-rated occupational role functioning. Use of acute care services reflected self-reported psychiatric hospitalization and emergency service use. Change of health state was determined over the 3-year period. A patient was classified as having a sustained favorable long-term outcome if their health state values had the closest distance to the defined "best baseline cluster" at each point over the length of the study. Stepwise logistic regression was used to determine baseline predictors of sustained favorable long-term outcome.

Results

At baseline, 5 distinct health state clusters were identified, ranging from "best" to "worst." Of 1635 patients with sufficient data, only 157 (10%) experienced sustained favorable long-term outcome during the 2-years postbaseline. The baseline predictors associated with sustained favorable long-term outcome included better quality of life, more daily activities, patient-reported clearer thinking from medication, better global functioning, being employed, not being a victim of a crime, not having received individual therapy, and not having received help with shopping and leisure activities.

Conclusions

Only a small percentage of patients achieved sustained favorable long-term outcome in this study, suggesting there continues to be a great need for improvement in the treatment of schizophrenia. Findings suggest that clinicians could make early projections of health states and identify those patients more likely to achieve favorable long-term outcomes enabling early therapeutic interventions to enhance benefits for patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Stroup TS: Heterogeneity of treatment effects in schizophrenia. Am J Med. 2007, 120 (Suppl 1): S26-S31.CrossRefPubMed Stroup TS: Heterogeneity of treatment effects in schizophrenia. Am J Med. 2007, 120 (Suppl 1): S26-S31.CrossRefPubMed
2.
go back to reference Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL, Kane JM: Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res. 2008, 102: 230-240.CrossRefPubMed Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL, Kane JM: Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res. 2008, 102: 230-240.CrossRefPubMed
3.
go back to reference Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A: Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull. 2008, 34: 1163-1171. 10.1093/schbul/sbm134.CrossRefPubMed Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A: Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull. 2008, 34: 1163-1171. 10.1093/schbul/sbm134.CrossRefPubMed
4.
5.
go back to reference Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005, 353: 1209-1223. 10.1056/NEJMoa051688.CrossRefPubMed Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005, 353: 1209-1223. 10.1056/NEJMoa051688.CrossRefPubMed
6.
go back to reference Miyamoto S, Duncan GE, Marx CE, Lieberman JA: Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005, 10: 79-104. 10.1038/sj.mp.4001556.CrossRefPubMed Miyamoto S, Duncan GE, Marx CE, Lieberman JA: Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005, 10: 79-104. 10.1038/sj.mp.4001556.CrossRefPubMed
7.
go back to reference Ayuso-Gutiérrez JL, del Río Vega JM: Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res. 1997, 28: 199-206. 10.1016/S0920-9964(97)00131-X.CrossRefPubMed Ayuso-Gutiérrez JL, del Río Vega JM: Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res. 1997, 28: 199-206. 10.1016/S0920-9964(97)00131-X.CrossRefPubMed
8.
go back to reference Perkins DO: Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002, 63: 1121-1128. 10.4088/JCP.v63n1206.CrossRefPubMed Perkins DO: Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002, 63: 1121-1128. 10.4088/JCP.v63n1206.CrossRefPubMed
9.
go back to reference Thieda P, Beard S, Richter A, Kane J: An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv. 2003, 54: 508-516. 10.1176/appi.ps.54.4.508.CrossRefPubMed Thieda P, Beard S, Richter A, Kane J: An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv. 2003, 54: 508-516. 10.1176/appi.ps.54.4.508.CrossRefPubMed
10.
go back to reference Liu-Seifert H, Adams DH, Kinon BJ: Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 2005, 3: 21-10.1186/1741-7015-3-21.CrossRefPubMedPubMedCentral Liu-Seifert H, Adams DH, Kinon BJ: Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 2005, 3: 21-10.1186/1741-7015-3-21.CrossRefPubMedPubMedCentral
11.
go back to reference Levine SZ, Leucht S: Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biol Psychiatry. 2010, 68: 86-92. 10.1016/j.biopsych.2010.01.012.CrossRefPubMed Levine SZ, Leucht S: Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biol Psychiatry. 2010, 68: 86-92. 10.1016/j.biopsych.2010.01.012.CrossRefPubMed
12.
go back to reference Rabinowitz J, Levine SZ, Haim R, Häfner H: The course of schizophrenia: progressive deterioration, amelioration or both?. Schizophr Res. 2007, 91: 254-258. 10.1016/j.schres.2006.12.013.CrossRefPubMed Rabinowitz J, Levine SZ, Haim R, Häfner H: The course of schizophrenia: progressive deterioration, amelioration or both?. Schizophr Res. 2007, 91: 254-258. 10.1016/j.schres.2006.12.013.CrossRefPubMed
13.
go back to reference Lambert M, Schimmelmann BG, Naber D, Schacht A, Karow A, Wagner T, Czekalla J: Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry. 2006, 67: 1690-1697. 10.4088/JCP.v67n1104.CrossRefPubMed Lambert M, Schimmelmann BG, Naber D, Schacht A, Karow A, Wagner T, Czekalla J: Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry. 2006, 67: 1690-1697. 10.4088/JCP.v67n1104.CrossRefPubMed
14.
go back to reference Lipkovich IA, Deberdt W, Csernansky JG, Buckley P, Peuskens J, Kollack-Walker S, Rotelli M, Houston JP: Defining "good" and "poor" outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach. Psychiatry Res. 2009, 170: 161-167. 10.1016/j.psychres.2008.09.004.CrossRefPubMed Lipkovich IA, Deberdt W, Csernansky JG, Buckley P, Peuskens J, Kollack-Walker S, Rotelli M, Houston JP: Defining "good" and "poor" outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach. Psychiatry Res. 2009, 170: 161-167. 10.1016/j.psychres.2008.09.004.CrossRefPubMed
15.
go back to reference Schennach-Wolff R, Jäger M, Seemüller F, Obermeier M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Huff W, Heuser I, Maier W, Lemke MR, Rüther E, Buchkremer G, Gastpar M, Möller HJ, Riedel M: Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders. Schizophr Res. 2009, 113: 210-217. 10.1016/j.schres.2009.05.032.CrossRefPubMed Schennach-Wolff R, Jäger M, Seemüller F, Obermeier M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Huff W, Heuser I, Maier W, Lemke MR, Rüther E, Buchkremer G, Gastpar M, Möller HJ, Riedel M: Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders. Schizophr Res. 2009, 113: 210-217. 10.1016/j.schres.2009.05.032.CrossRefPubMed
16.
go back to reference Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW: Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006, 67: 453-460. 10.4088/JCP.v67n0317.CrossRefPubMed Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW: Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006, 67: 453-460. 10.4088/JCP.v67n0317.CrossRefPubMed
17.
go back to reference Lehman AF, Fischer EP, Postrado L, Delahanty J, Johnstone BM, Russo PA, Crown WH: The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): an instrument to assess outcomes of schizophrenia care. Schizophr Bull. 2003, 29: 247-256.CrossRefPubMed Lehman AF, Fischer EP, Postrado L, Delahanty J, Johnstone BM, Russo PA, Crown WH: The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): an instrument to assess outcomes of schizophrenia care. Schizophr Bull. 2003, 29: 247-256.CrossRefPubMed
18.
go back to reference Lehman AF: A quality of life interview for the chronically mentally ill. Evaluation and Program Planning. 1988, 11: 51-62. 10.1016/0149-7189(88)90033-X.CrossRef Lehman AF: A quality of life interview for the chronically mentally ill. Evaluation and Program Planning. 1988, 11: 51-62. 10.1016/0149-7189(88)90033-X.CrossRef
19.
go back to reference Fischer EP: Mental health outcome module development and testing: development and initial validation of the schizophrenia outcomes module - final report, SDR Grant #91,005. 1993, Washington, DC: Department of Veterans Affairs Fischer EP: Mental health outcome module development and testing: development and initial validation of the schizophrenia outcomes module - final report, SDR Grant #91,005. 1993, Washington, DC: Department of Veterans Affairs
20.
go back to reference Cuffel BJ, Fischer EP, Owen RR, Smith GR: An instrument for measurement of outcomes of care for schizophrenia. Issues in development and implementation. Eval Health Prof. 1997, 20: 96-108. 10.1177/016327879702000107.CrossRefPubMed Cuffel BJ, Fischer EP, Owen RR, Smith GR: An instrument for measurement of outcomes of care for schizophrenia. Issues in development and implementation. Eval Health Prof. 1997, 20: 96-108. 10.1177/016327879702000107.CrossRefPubMed
21.
go back to reference Ware J, Kosinski M, Keller SD: A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996, 34: 220-233. 10.1097/00005650-199603000-00003.CrossRefPubMed Ware J, Kosinski M, Keller SD: A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996, 34: 220-233. 10.1097/00005650-199603000-00003.CrossRefPubMed
22.
go back to reference Mayfield D, McLeod G, Hall P: The CAGE questionnaire: validation of a new alcoholism screening instrument. Am J Psychiatry. 1974, 131: 1121-1123.PubMed Mayfield D, McLeod G, Hall P: The CAGE questionnaire: validation of a new alcoholism screening instrument. Am J Psychiatry. 1974, 131: 1121-1123.PubMed
23.
go back to reference Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987, 13: 261-276.CrossRefPubMed Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987, 13: 261-276.CrossRefPubMed
24.
go back to reference Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979, 134: 382-389. 10.1192/bjp.134.4.382.CrossRefPubMed Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979, 134: 382-389. 10.1192/bjp.134.4.382.CrossRefPubMed
25.
go back to reference Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970, 212: 11-19.CrossRefPubMed Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970, 212: 11-19.CrossRefPubMed
26.
go back to reference Guy W: ECDEU Assessment manual for psychopharmacology, revised. 1976, Rockville, MD: US Department of Health, Education, and Welfare, Publication ADM 76-338 Guy W: ECDEU Assessment manual for psychopharmacology, revised. 1976, Rockville, MD: US Department of Health, Education, and Welfare, Publication ADM 76-338
27.
go back to reference American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 1994, Washington, DC: American Psychiatric Association, Fourth American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 1994, Washington, DC: American Psychiatric Association, Fourth
28.
go back to reference Heinrichs DW, Hanlon TE, Carpenter WT: The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984, 10: 388-398.CrossRefPubMed Heinrichs DW, Hanlon TE, Carpenter WT: The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984, 10: 388-398.CrossRefPubMed
29.
go back to reference Marder SR, Davis JM, Chouinard G: The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997, 58: 538-546. 10.4088/JCP.v58n1205.CrossRefPubMed Marder SR, Davis JM, Chouinard G: The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997, 58: 538-546. 10.4088/JCP.v58n1205.CrossRefPubMed
30.
go back to reference Ward JH: Hierarchical grouping to optimize an objective function. J Amer Statistical Assoc. 1963, 58: 236-244. 10.2307/2282967.CrossRef Ward JH: Hierarchical grouping to optimize an objective function. J Amer Statistical Assoc. 1963, 58: 236-244. 10.2307/2282967.CrossRef
31.
go back to reference Levine SZ, Rabinowitz J: Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophr Bull. 2010, 36: 624-632. 10.1093/schbul/sbn120.CrossRefPubMed Levine SZ, Rabinowitz J: Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophr Bull. 2010, 36: 624-632. 10.1093/schbul/sbn120.CrossRefPubMed
Metadata
Title
Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study
Authors
Gebra B Cuyún Carter
Denái R Milton
Haya Ascher-Svanum
Douglas E Faries
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2011
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-11-143

Other articles of this Issue 1/2011

BMC Psychiatry 1/2011 Go to the issue